T2* MRI Analysis for Sarcoma

An Exploratory, Pilot Study Evaluating T2* Imaging for Adult Sarcoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03658343

Enrollment

Registered

2018-09-05

Start date

2018-09-18

Completion date

2022-02-25

Last updated

2025-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Magnetic Resonance Imaging, Radiotherapy, Sarcoma

Keywords

soft tissue sarcoma

Brief summary

T2\* imaging is a method to identify labile iron pools in tumor cells. These iron pools may be linked to better treatment outcomes for specific types of therapy. This is a small pilot study to see if radiation therapy changes the amount of iron in a sarcoma tumor.

Interventions

DIAGNOSTIC_TESTT2* Imaging

T2\* imaging sequences for MRI

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* pathologically confirmed Sarcoma, by biopsy or excision * prescribed radiation therapy as per standard of care * treatment to begin within 5 weeks after surgery or biopsy * ECOG 0, 1, or 2 * ability and willingness to provide informed consent

Exclusion criteria

* \< 18 years of age

Design outcomes

Primary

Measure	Time frame	Description
Change in ferric iron levels detected by T2* MRI	baseline and 8 weeks	Change from baseline in Fe3+ iron levels

Secondary

Measure	Time frame	Description
Change in ferrous iron levels detected by T2* MRI	Baseline and 8 weeks	Change from baseline in Fe2+ iron levels

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026